Right-Sided Extravalvular Damage: An Overlooked Driver of Risk Model Failure in Low-Flow, Low-Gradient Aortic Stenosis

右侧瓣外损伤:低流量、低梯度主动脉瓣狭窄风险模型失败的一个被忽视的驱动因素

阅读:2

Abstract

BACKGROUND: The Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score is guideline-endorsed for estimating procedural risk in aortic stenosis (AS) but tends to overestimate long-term mortality after transcatheter aortic valve replacement (TAVR). This study aimed to evaluate whether markers of right-sided extravalvular damage improve STS-PROM's performance in predicting 1-year mortality post-TAVR for patients with low-flow, low-gradient AS. METHODS: Four hundred ten patients with valve area ≤1.0 cm(2), stroke volume index ≤35 mL/m(2), and mean gradient <40 mm Hg who underwent TAVR were retrospectively stratified into low (<4%), moderate (4%-8%), and high (>8%) STS-PROM risk groups. Performance of an enhanced logistic regression model incorporating both STS-PROM and right-sided extravalvular damage (defined as moderate+ pulmonary hypertension, moderate+ tricuspid regurgitation, or right ventricular systolic dysfunction) was assessed using receiver operating characteristic curves, net reclassification index (NRI), and integrated discrimination index (IDI). RESULTS: Right-sided extravalvular damage was independently associated with increased 1-year mortality (OR, 2.45; 95% CI, 1.34-4.46; P < .01). Model fit improved with its addition (Δχ(2) = 8.68, P < .01), and discrimination increased (IDI = 0.02, P = .01). NRI analysis showed improved survivor classification (non-event NRI = 0.10, P < .01). The largest gain was in moderate-risk patients (area under the curve, 0.46-0.67; P = .06). CONCLUSIONS: Markers of right-sided extravalvular damage conferred meaningful prognostic value in low-flow, low-gradient AS by correcting the STS-PROM score's tendency to overestimate post-TAVR mortality. The added value of these markers was most pronounced in moderate-risk patients, for whom existing tools appear least reliable. These markers may improve patient selection for TAVR and merit evaluation in other severe AS phenotypes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。